A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, MDS/Myeloid Panel, -5/5q-, -7/7q-, +8,20q-
Test Code19799
CPT Codes
88271 (x6), 88275 (x3)
Preferred Specimen
5 mL whole blood or 3 mL bone marrow collected in a sodium heparin (green-top) tube
Minimum Volume
1 mL
Other Acceptable Specimens
Sodium heparin (royal blue-top) tube • Sodium heparin lead-free (tan-top) tube
Instructions
Submit 3-5 mL whole blood or 1-3 mL bone marrow collected in a sodium heparin tube.
Transport Temperature
Room temperature
Specimen Stability
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not Reject.
Methodology
Fluorescence in situ Hybridization (FISH)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 5-7 days
Clinical Significance
Prognostic investigation in patients with myelodysplasia or other myeloid malignancies. Among the patients with myelodysplastic syndromes (MDS), 45-50% have a least one chromosome rearrangement, the most common of which can be detected using this fluorescence in situ hydridization (FISH) panel (-5/5q-,-7/7q-,+8,20q-). This panel of FISH probes can increase the detection rate of chromosome abnormalities at diagnosis and aid in follow-up testing for clinically significant chromosome abnormalities in MDS. The identification of the specific chromosome regions involved in a patient's disease may play a significant role in treatment decisions as MDS targeted therapies are developed.